# A. Oliver Sartor

Source: https://nuclide.cc/people/oliver-sartor/  
Nuclide record `oliver-sartor` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.

## Summary

Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; radioligand; trialist
- Role: Professor of Medical Oncology and Urology, Mayo Clinic
- Specialisms: Prostate cancer; Radioligand therapy; PSMA-targeted therapy; Radium-223

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Oliver_Sartor
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Radium-223](https://nuclide.cc/isotopes/ra-223/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [Mayo Clinic](https://nuclide.cc/institutions/mayo-clinic/)
- trials: [ALSYMPCA](https://nuclide.cc/trials/alsympca/), [PSMAfore](https://nuclide.cc/trials/psmafore/), [VISION](https://nuclide.cc/trials/vision/)
- key papers: [Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC](https://nuclide.cc/key-papers/paper-tagawa-ac225-j591-jco-2024/), [PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC](https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- pairings: [Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617](https://nuclide.cc/pairings/docetaxel-then-lu177-psma/)

---
JSON: https://nuclide.cc/api/v1/entities/oliver-sartor.json